T1	PROC 47 105	Estudio en fase III, aleatorizado, doble ciego, controlado
T2	PROC 112 146	evaluar la eficacia y la seguridad
T3	PROC 153 170	terapia combinada
#1	AnnotatorNotes T3	C0009429; Combined Modality Therapy; Therapeutic or Preventive Procedure
T4	CHEM 175 181	VX-121
T5	LIVB 185 192	sujetos
#2	AnnotatorNotes T5	C0681850; Study Subject; Group
T6	DISO 197 214	fibrosis quística
#3	AnnotatorNotes T6	C0010674; Cystic Fibrosis; Disease or Syndrome
T7	DISO 229 246	Fibrosis quística
#4	AnnotatorNotes T7	C0010674; Cystic Fibrosis; Disease or Syndrome
T8	LIVB 279 285	sujeto
#5	AnnotatorNotes T8	C0681850; Study Subject; Group
T9	LIVB 292 305	representante
#6	AnnotatorNotes T9	C0600419; Patient Agent; Group | C1708966; Medical Equipment Company Technician or Representative; Professional or Occupational Group
T10	PROC 376 400	consentimiento informado
#7	AnnotatorNotes T10	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T11	PROC 402 405	ICF
T12	PROC 501 508	visitas
T13	PROC 533 544	tratamiento
#8	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 581 603	pruebas de laboratorio
#9	AnnotatorNotes T14	C0022885; Laboratory Procedures; Laboratory Procedure
T15	PROC 609 631	pautas anticonceptivas
T16	PROC 640 654	procedimientos
T17	Neg_cue 671 673	No
T18	PROC 684 698	consentimiento
T19	Negated 684 698	consentimiento
T20	PROC 776 787	Tratamiento
#10	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	CHEM 804 811	fármaco
#11	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T22	PROC 856 884	interrupción(es) del fármaco
T23	Neg_cue 927 929	no
T24	PROC 930 968	interrumpió permanentemente el fármaco
T25	PROC 996 1003	visitas
T26	PROC 1032 1038	visita
T27	PROC 1065 1076	tratamiento
#12	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	PROC 1134 1156	régimen de tratamiento
T29	DISO 1173 1175	FQ
#13	AnnotatorNotes T29	C0010674; Cystic Fibrosis; Disease or Syndrome
T30	DISO 1275 1287	comorbilidad
#14	AnnotatorNotes T30	C0206308; Dual diagnosis (psychiatry); Finding | C1275743; Co-morbid conditions; Finding
T31	LIVB 1306 1318	investigador
#15	AnnotatorNotes T31	C0035173; Research Personnel; Professional or Occupational Group
T32	PROC 1399 1425	administración del fármaco
T33	LIVB 1441 1447	sujeto
#16	AnnotatorNotes T33	C0681850; Study Subject; Group
T34	LIVB 1509 1516	mujeres
#17	AnnotatorNotes T34	C0043210; Woman; Population Group | C0242665; wife; Family Group
T35	PROC 1533 1551	prueba de embarazo
#18	AnnotatorNotes T35	C0032976; Pregnancy Tests; Diagnostic Procedure
T36	Neg_cue 1552 1560	negativa
T37	PROC 1567 1573	visita
T38	Date 1578 1583	día 1
T39	CHEM 1622 1629	fármaco
#19	AnnotatorNotes T39	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T40	DISO 1658 1683	intolerancia a las drogas
T41	LIVB 1750 1756	sujeto
#20	AnnotatorNotes T41	C0681850; Study Subject; Group
T42	LIVB 1772 1784	investigador
#21	AnnotatorNotes T42	C0035173; Research Personnel; Professional or Occupational Group
T43	LIVB 1795 1802	sujetos
#22	AnnotatorNotes T43	C0681850; Study Subject; Group
T44	DISO 1823 1830	alergia
#23	AnnotatorNotes T44	C0020517; Hypersensitivity; Pathologic Function
T45	DISO 1833 1850	hipersensibilidad
#24	AnnotatorNotes T45	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T46	CHEM 1854 1861	fármaco
#25	AnnotatorNotes T46	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T47	Date 1893 1899	actual
T48	Neg_cue 1949 1951	no
T49	PROC 2013 2040	estudio no intervencionista
T50	PROC 2056 2079	estudios de observación
#26	AnnotatorNotes T50	C1518527; Observational Study; Research Activity
T51	PROC 2085 2105	estudios de registro
T52	PROC 2135 2157	extracciones de sangre
#27	AnnotatorNotes T52	C0419338; Blood withdrawal NOS; Diagnostic Procedure
T53	Neg_cue 2158 2161	sin
T54	PROC 2165 2191	administración del fármaco
T55	PROC 433 459	formulario de asentimiento
T56	Negated 930 968	interrumpió permanentemente el fármaco
T57	Negated 1533 1551	prueba de embarazo
T58	LIVB 1452 1459;1477 1497	Mujeres período de lactancia
T59	LIVB 1452 1471	Mujeres embarazadas
T60	PROC 1906 1943	ensayo de un fármaco en investigación
T61	PROC 1959 1976	estudio principal
T62	Negated 1959 1976	estudio principal
T63	Negated 2165 2191	administración del fármaco
T64	Observation 329 339	autorizado
T65	Observation 447 459	asentimiento
T66	Observation 464 473	Dispuesto
T67	Observation 476 492	capaz de cumplir
T68	Quantifier_or_Qualifier 788 796	completo
T69	Quantifier_or_Qualifier 942 957	permanentemente
T70	Observation 983 1003	completó las visitas
T71	Quantifier_or_Qualifier 1025 1031	última
T72	Quantifier_or_Qualifier 1039 1049	programada
T73	Quantifier_or_Qualifier 1157 1164	estable
T74	Observation 1182 1214	completar la participación en el
T75	Observation 1326 1350	confundir los resultados
T76	Observation 1376 1382	riesgo
T77	Result_or_Value 1552 1560	negativa
T78	CONC 1604 1617	primera dosis
T79	Observation 1725 1731	riesgo
T80	Observation 1879 1912	Participación actual en un ensayo
T81	Quantifier_or_Qualifier 1967 1976	principal
T82	Patient 185 192	sujetos
T83	Patient 279 285	sujeto
T84	Other 292 316	representante legalmente
T85	History_of 1275 1287	comorbilidad
T86	Other 1306 1318	investigador
T87	Patient 1441 1447	sujeto
T88	Patient 1452 1497	Mujeres embarazadas o en período de lactancia
T89	Patient 1509 1516	mujeres
T90	History_of 1658 1683	intolerancia a las drogas
T91	Patient 1750 1756	sujeto
T92	Other 1772 1784	investigador
T93	Patient 1795 1802	sujetos
T94	History_of 1823 1830	alergia
T95	History_of 1833 1850	hipersensibilidad
